MolDX: Inivata™, InvisionFirst®, Liquid Biopsy for Patients with Lung Cancer

InVisionFirst (Inivata) plasma-based comprehensive genomic profiling is covered for patients with advanced (Stage IIIB/IV) non-small cell lung cancer when tissue-based CGP is infeasible (QNS or biopsy contraindicated) and results for EGFR, ALK, ROS1, and BRAF are not available, as well as for patients at progression who meet these conditions or who are progressing on EGFR TKIs. If no alteration is detected or ctDNA is insufficient/not detected on plasma testing, tissue-based genotyping should be considered.

"Plasma-based comprehensive genomic profiling (InVisionFirst) is covered for patients with advanced non-small cell lung cancer (Stage IIIB/IV) at initial diagnosis when results for EGFR SNVs/indels,..."

Sign up to see full coverage criteria, indications, and limitations.